Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 9, 2022 (5 years ago)

Diazepam Oral Solution

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: Out of specification results for related substances.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Diazepam Oral Solution (Concentrate), 25 mg per 5 mL (5 mg/mL), 30 mL BOTTLE and DROPPER, Rx Only, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136, NDC 0527-1768-36.

Affected NDC 0527-1768-36

Compare with the code on your package — it is the most precise check available.

Drug: Diazepam

Recalling firm
Lannett Company, Inc.
NDC code
0527-1768-36
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0558-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Diazepam recalls

See all
Class III · Low risk

Diazepam Rectal Gel

Labeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton.

Terminated Labeling / mix-up Valeant Pharmaceuticals North America LLC NDC 68682-650-20 D-1041-2018
Class II · Moderate risk

Diazepam 5 mg/mL injectable packaged in an amber glass injectable vial

Lack of Assurance of Sterility: Martin Avenue Pharmacy, Inc. is conducting a voluntary recall of all compounded sterile preparations within expiry. The recall is being initiated in connection with a recent FDA inspection due to observations associated with certain quality control procedures that present a risk to sterility assurance.

Terminated Sterility / contamination Martin Avenue Pharmacy, Inc. D-0078-2015
Class II · Moderate risk

Diazepam Injection

Lack of assurance of sterility: ineffective crimp on fliptop vials that may result in leaking at the neck of the vials.

Terminated Sterility / contamination Hospira Inc. NDC 0409-3213-12 D-927-2013

Other recalls by Lannett Company, Inc.

All 2022 recalls
Class II · Moderate risk

Dextroamphetamine Saccharate

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

Ongoing Labeling / mix-up Lannett Company Inc. D-0660-2026
Class II · Moderate risk

Niacin Extended-release Tablets

Failed Dissolution Specifications: during 12M LT stability testing OOS low for Stage 3 dissolution at the 24-hour timepoint.

Ongoing Dissolution failure Lannett Company Inc. NDC 62175-322-46 D-0584-2026
Class III · Low risk

Primidone Tablets USP

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Lannett Company Inc. NDC 0527-1231-01 D-0533-2026